论文部分内容阅读
目的 :在人源抗HBsFab表达载体构建、抗体片段表达及纯化成功后 ,进行放射免疫显像研究 ,以评价其在动物模型中的免疫导向活性。方法 :用13 1I标记人源抗HBsFab ,经腹腔注射 1,3,5 ,7d后行裸鼠人肝癌模型放射免疫显像 ,于第 7天作组织分布测定 ,并以鼠源抗HBsAg单抗为对照进行比较。 结果 :实验组在标记抗体注入后第 3天即获阳性显像 ,第 5天更加清晰 ,此时人源抗HBsFab、鼠源单抗及无关Fab的瘤 /肝放射性比值分别为 5 .4,4.0和 0 .9。结论 :人源抗HBsFab具有良好的导向活性 ,为其用于肝癌的导向治疗提供了实验依据。
OBJECTIVE: To study the immunogenicity of human anti-HBsFab expression vector in animal models by radioimmunoassay after its construction, antibody fragment expression and purification. Methods: Human anti-HBsFab was labeled with 131I and radioimmunoimaging was performed in nude mice on day 1, 3, 5 and 7 after intraperitoneal injection. Tissue distribution was determined on the 7th day. The murine anti-HBsAg monoclonal antibody Compare for comparison. Results: In the experimental group, the positive images were obtained on the third day after the labeled antibody was injected and clearer on the fifth day. The tumor / liver radioactivity ratios of human anti-HBsFab, murine monoclonal antibody and unrelated Fab were 5.5, 4.0 and 0.9. Conclusion: The human anti-HBsFab has good targeting activity and provides experimental evidence for the targeted therapy of liver cancer.